Practical advice for determining the role of BCR‐ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
Data demonstrating the superiority of nilotinib over imatinib in the frontline treatment of
chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are …
chronic myeloid leukemia (CML) and ongoing studies with dasatinib and bosutinib are …
Abl tyrosine kinase inhibitors for overriding Bcr–Abl/T315I: from the second to third generation
R Tanaka, S Kimura - Expert review of anticancer therapy, 2008 - Taylor & Francis
Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence
of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary …
of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate. However, primary and secondary …
BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features
Introduction 'yyto put together such apparently dissimilar diseases as chronic granulocytic
leukaemia, polycythemia, myeloid metaplasia and di Guglielmo's syndrome may …
leukaemia, polycythemia, myeloid metaplasia and di Guglielmo's syndrome may …
Synthesis of 8-aminoquinolines as inhibitors of tyrosine kinases
E Rosso - 2010 - dspace.unive.it
Chronic myelogenous leukemia (CML), characterized by unregulated proliferation of
myeloid cells in the bone marrow, accounts for 15 to 20% of all adult leukemia cases in the …
myeloid cells in the bone marrow, accounts for 15 to 20% of all adult leukemia cases in the …